Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00345657
Status:
COMPLETED
Last Update Posted:
2006-06-28
First Post:
2006-06-27
Brief Title:
Efficacy Study of Extended-Release NiacinLovastatin Versus Usual Care
Sponsor:
In His Image
Organization:
In His Image
Study Overview
Official Title:
Extended-Release NiacinLovastatin Versus Usual Care for Treatment of Dyslipidemia in a Primary Care Setting EXTEND Study
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the benefits of combination niacin ERlovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines
Detailed Description:
Both LDL and HDL are important contributors in the pathophysiology of atherosclerosis and coronary artery disease CAD however HDL is often ignored in primary care The combination of niacin extended-release ERlovastatin in a single tablet formulation Advicor may be the most effective therapeutic option for simultaneously correcting both of these lipoprotein abnormalities to reduce CAD risk The purpose of this study is to investigate the benefits of combination niacin ERlovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None